Economic evaluation alongside factorial trials:a systematic review of empirical studies by Frempong, Samuel et al.
 
 
University of Birmingham
Economic evaluation alongside factorial trials
Frempong, Samuel; Goranitis, Ilias; Oppong, Raymond
DOI:
10.1586/14737167.2015.1076336
License:
None: All rights reserved
Document Version
Peer reviewed version
Citation for published version (Harvard):
Frempong, S, Goranitis, I & Oppong, R 2015, 'Economic evaluation alongside factorial trials: a systematic review
of empirical studies', Expert Review of Pharmacoeconomics & Outcomes Research, vol. 15, no. 5, pp. 801-811.
https://doi.org/10.1586/14737167.2015.1076336
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
“This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
on 07/08/2015, available online: http://wwww.tandfonline.com/10.1586/14737167.2015.1076336
Checked October 2015
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
For Peer Review Only
 
 
 
 
 
 
Economic evaluation alongside factorial trials: a systematic 
review of empirical studies 
 
 
Journal: Expert Review of Pharmacoeconomics & Outcomes Research 
Manuscript ID: ERP-2015-0046.R2 
Manuscript Type: Reviews 
Keywords: 
cost-benefit, cost-utility analysis, Factorial design, economic evaluation, 
Factorial trial 
  
 
 
URL: https://mc.manuscriptcentral.com/erp   Email: tanya.stezhka@informa.com
Expert Review of Pharmacoeconomics & Outcomes Research
For Peer Review Only
 
  
Table 1: Search strategies used 
DATABASE SEARCHED TIMESPAN SEARCH STRATEGY 
NHS EED All years (economic evaluation*) and (factorial design*) 
 
Embase 1974 to 2013 July 30 1. "cost"/ or cost-utility analysis.mp. or "cost benefit analysis"/ or "health care 
cost"/ 
or "quality of life"/ (442989) 
2. cost-effective$.mp. (140957) 
3. economic evaluation$.mp. (13687) 
4. 1 or 2 or 3 (544342) 
5. factorial design$.mp. (1111) 
6. 4 and 5 (39) 
 
EconLit All years S1 economic evaluation* 
S2 cost-utility analysis 
S3 cost-benefit analysis 
S4 cost-effective* 
S5 S1 OR S2 OR S3 OR S4 
S6 factorial design* 
S7 S5 AND S6 
 
COCHRANE All years #1 economic evaluation*  
#2 factorial trial* 
#3 #1 and #2 
 
Science Citation Index (Expanded) All years (Factorial trial*) and (economic evaluation*)  
 
Conference proceedings citation All years (Factorial trial*) and (economic evaluation*) 
 
Ovid MEDLINE(R) 1946 to July Week 3 2013 1. Quality-Adjusted Life Years/ or Cost-Benefit Analysis/ or Health Care Costs/ 
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or 
cost-utility analysis.mp. or "Quality of Life"/ (194798) 
2. cost-effective$.mp. (70146) 
3. economic evaluation$.mp. (6062) 
4. 1 or 2 or 3 (236930) 
5. factorial design$.mp. (961) 
6. 4 and 5 (30) 
 
BioMed Central All years (Factorial trial*) and (economic evaluation*) 
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Table 2: Summary of the studies used in the review 
 AUTHOR(S) 
AND YEAR 
OF 
PUBLICATI
ON 
TYPE OF 
FACTORI
AL TRIAL 
TIME 
HORIZON 
OF THE 
RESEARC
H 
OBJECTIVE(
S) OF THE 
RESEARCH 
TYPE OF 
ECONOMIC 
EVALUATI
ON 
PERSPECTI
VE 
SAMPL
E SIZE 
CONTRO
L 
GROUP 
USED 
PRIMARY 
OUTCOME(
S) 
SENSITIVIT
Y ANALYSIS 
UNDERTAK
EN 
METHOD OF 
ANALYSIS AND 
ITS 
APPROPRITENE
SS TO THE 
RESEARCH 
OBJECTIVES 
CONSIDERED  
INTERACTIO
NS IN 
ECONOMIC 
OUTCOMES 
1 Dangour et al., 
2011 
2x2 Two (2) 
years. 
The 
objective(s) of 
the research 
was to assess 
the 
effectiveness 
and cost-
effectiveness 
of the Chilean 
national 
nutritional 
supplementatio
n program on 
decreasing the 
incidence of 
pneumonia and 
a training 
exercise 
program to 
increase 
walking 
capacity in 
older people in 
Santiago Chile. 
Cost-
effectiveness 
analysis. 
Societal 2799 Usual care Cost/unit 
effect 
Not stated. At-the-margins 
analysis 
 
. 
No 
2 The UK 
BEAM trial 
team, 2004 
2x2 One (1) 
year 
The objective 
of the research 
was to assess 
the cost-
effectiveness 
of adding 
spinal 
manipulation, 
exercise or a 
combination of 
the treatments 
to “best care” 
for patients 
Cost-utility 
analysis 
Health service 1287 placebo  cost/QALY  One-way 
sensitivity 
analysis for 
three different 
scenarios. 
Within-the-table 
analysis 
 
 
Yes 
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consulting with 
low back pain.   
3 Barton et al., 
2009 
2x2 Two (2) 
years 
The objective 
of the research 
was to estimate 
the cost-
effectiveness 
of four 
different 
lifestyle 
interventions 
for knee pain 
Cost-utility 
analysis 
Health service 389 Usual care Cost/QALY  Probabilistic-
sensitivity 
analysis. 
Within-the-table 
analysis. 
 
 
No 
4 Jafar et al., 
2011 
2x2 Two (2) 
years 
The objective 
of the research 
was to assess 
the cost-
effectiveness 
of Home 
Health 
Education 
(HHE) 
and/special 
training of GPs 
on the blood 
pressure levels 
of adults aged 
40yrs or above 
with 
hypertension 
Cost-utility 
analysis 
Societal 1341 placebo cost/DALY  Probabilistic 
sensitivity 
analysis 
Within-the-table 
analysis 
 
 
No 
5 Pinto et al., 
2013 
2x2 One (1) 
year 
The objective 
of the trial was 
to evaluate the 
cost-
effectiveness 
of manual 
physiotherapy, 
exercise 
physiotherapy 
Cost-utility 
analysis. 
Health service 
and societal  
206 placebo Cost/QALY  One-way 
sensitivity 
analysis 
Within-the-table 
analysis 
 
 
No 
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and a 
combination of 
the two for 
patients with 
osteoarthritis 
of the hip or 
knee 
6 Morris et al., 
2011 
2x2 One (1) 
year 
The objective 
of the research 
was to assess 
the cost 
effectiveness 
of a 
rehabilitation 
program and 
educational 
booklet each 
compared with 
usual care for 
the post-
operative 
management of 
patients 
undergoing 
surgery 
Cost-utility 
analysis 
Health service 
and societal 
338 placebo  cost/QALY  nonparametric 
bootstrapping 
At-the-margins 
analysis 
 
 
 
No 
7 Thomas et al., 
2005 
2x2 Two (2) 
years 
The objective 
was to 
compare the 
cost-
effectiveness 
of exercise and 
monthly 
telephone 
support for the 
treatment of 
knee pain. 
Cost-
effectiveness 
analysis 
Health service 
perspective 
786 Usual care Cost/unit 
effect 
nonparametric 
bootstrapping 
At-the-margins 
analysis 
 
 
No 
8 Campbell et 
al., 2005 
2x2 One (1) 
year 
To assess the 
efficacy and 
cost-
effectiveness 
of a home 
safety program 
and a home 
exercise 
Cost-
effectiveness 
analysis 
societal 391 Usual 
care 
Cost/unit 
effect 
one-way 
sensitivity 
analysis 
At-the-margins 
analysis 
 
 
No 
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program to 
reduce falls 
and injuries in 
older people 
with low 
vision.    
 
9 
 
 
 
 
 
Lindgren et al., 
2009 
2x2 Three (3) 
years 
To assess the 
cost 
effectiveness 
of four 
alternative 
treatment 
strategies 
in patients with 
hypertension 
and three or 
more 
cardiovascular 
risk 
factors in the 
UK 
Cost-utility 
analysis 
Health service 
and societal 
perspectives 
19,257 Usual 
care 
Cost/QALY One-way 
sensitivity 
analysis and 
probabilistic 
sensitivity 
analysis 
Within-the table 
analysis 
 
 
 
 
 
 
 
 
 
 
 
 
No 
1
0 
Effing et al., 
2009 
2x2 One (1) 
year 
To assess the 
Cost-
effectiveness 
of self-
treatment of 
exacerbations 
on the severity 
of 
exacerbations 
in 
patients with 
COPD 
Cost-
effectiveness 
analysis 
Health service 142 Usual 
care 
Cost/unit 
effect 
Probabilistic 
sensitivity 
analysis 
At-the-margins No 
1
1 
Lewca et al., 
2013 
2x2 Five (5) 
years 
To assess the 
Effects and 
cost-
effectiveness 
of community 
mobilisation 
through 
women’s 
groups, and 
health 
education 
through female 
volunteer 
peer 
counsellors on 
Cost-
effectiveness 
analysis 
Health service 185888 placebo Cost/unit 
effect 
Not stated Within-the-table 
analysis 
No 
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rates of infant 
care, feeding, 
morbidity, and 
mortality.  
1
2 
Hollinghurst et 
al., 2008 
4x2 One (1) 
year 
An economic 
evaluation of 
therapeutic 
massage, 
exercise, and 
lessons in the 
Alexander 
technique for 
treating 
persistent back 
pain 
Cost-utility 
analysis and 
cost-
consequence 
analysis 
Health service, 
societal and 
patient  
579 Usual 
care 
Cost/QALY One-way 
sensitivity 
analysis and 
non-parametric 
bootstrapping 
Within-the-table 
analysis 
 
No 
1
3 
Bakkhai et al., 
2003 
2x2 One (1) 
year 
To assess the 
Cost-
Effectiveness 
of Coronary 
Stenting and 
Abciximab for 
Patients With 
Acute 
Myocardial 
Infarction 
Cost-utility 
analysis 
Health service 1703 Usual 
care 
Cost/QALY Non-
parametric 
bootstrapping 
Within-the-table 
analysis 
No 
1
4 
Boyle et al., 
2007 
2x2 One (1) 
year 
To assess the 
effect and 
economic 
evaluation of 
direct versus 
indirect and 
individual 
versus group 
modes of 
speech and 
language 
therapy 
for children 
with primary 
language 
impairment  
Cost-
effectiveness 
analysis 
patient 161 Usual 
care 
Cost/unit 
effect 
Non-
parametric 
bootstrapping 
Within-the-table 
analysis 
No 
1
5 
McBeth et al., 
2012 
2x2 One (1) 
year 
To assess the 
cost-
effectiveness 
of cognitive 
behaviour 
therapy, 
Exercise, 
Cost-utility 
analysis 
Health service 442 Usual 
care 
Cost/QALY Non-
parametric 
bootstrapping 
Within-the-table 
analysis 
No 
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or both for 
treating 
chronic 
widespread 
pain  
1
6 
Waterhouse et 
al., 2010 
2x2 One (1) 
year 
To assess the 
cost-
effectiveness 
of community 
versus hospital 
pulmonary 
rehabilitation 
for chronic 
obstructive 
pulmonary 
disease 
followed by 
telephone or 
conventional 
follow-up 
Cost-utility 
analysis 
Health service 240 Usual 
care 
Cost/QALY Non-
parametric 
bootstrapping 
Within-the-table 
analysis 
No 
 
 
Table 3: Summary of the main differences between the at-the-margins approach and the within-the-table approach 
Within-the-table approach At-the-margins approach 
All interventions within the trial are treated separately. E.g. in a 2x2  trial comparing interventions A, B, 
AB and O all arms are treated separately 
Considers the trial as separate overlapping trials. E.g. in a 2x2 trial comparing A,B,AB and O, all 
participants who received A (i.e. A and AB) are compared to those who did  not receive A (i.e. B and O)  
Takes interactions between interventions into account (i.e. assumes that the effects of intervention A are 
influenced by the inclusion of intervention B and vice versa) 
Assumes independence of interventions (i.e. the effects of intervention A are not influenced by the 
inclusion of intervention B and vice versa) 
The approach is less efficient ( i.e. effects of treatments are not based on the entire sample size) The approach is more efficient (i.e. treatment effects are based on the entire sample size) 
Estimates obtained are considered to be unbiased Estimates obtained are considered to be biased if interactions are present  
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Figure 1: Summary of the search strategy  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BioMed 
Central 
N=9 
Conference 
proceedings 
citation 
N=0 
Science 
citation 
index 
N=15 
Cochrane 
N=27 
EconLit 
N=0 
NHS EED 
N=15 
Embase 
N=39 
Medline 
N=30 
Total=135 
Duplicates 
N=18 
Unique papers after removal of 
duplicates 
N=117 
Papers removed after screening of 
titles and abstracts 
N=92 
Total papers retrieved and reviewed 
N= 25 
Papers that failed to 
meet the review criteria 
N= 13 
Papers left after second screening 
N=12 
Papers identified from screening 
the references of relevant papers 
N=4 
Total number of papers included in the 
review  
N= 16 
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2 
 
ABSTRACT 
 
Although economic evaluations have been carried out alongside factorial trials, there seems to be 
limited guidance/consensus on appropriate methods of analysis. Following Centre for Review and 
Dissemination guidance, a systematic review of published literature for all years was carried out to 
explore how economic evaluation alongside factorial trials have been conducted and only full 
economic evaluations conducted alongside factorial trials were included. A total of 16 relevant studies 
were identified and an assessment of these indicated that two methods: within-the-table and at-the-
margins approaches were used for the analysis. With the exception of one study, all others did not 
consider interactions in costs and outcomes or give a detailed explanation of why a particular 
approach was adopted. The authors recommend that additional guidance is needed and further 
research is required to evaluate the impact of alternative methods on policy recommendations and 
establish good practice methods for the economic analysis of factorial trials. 
Key words: cost-benefit analysis, cost-effectiveness, cost-utility analysis, economic evaluation, 
factorial design, factorial trial. 
  
Page 11 of 24
URL: https://mc.manuscriptcentral.com/erp   Email: tanya.stezhka@informa.com
Expert Review of Pharmacoeconomics & Outcomes Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
3 
 
INTRODUCTION 
Health economic evaluations are commonly used to inform resource allocation decisions in most 
industrialised nations and many funding bodies such as the UK National Institute for Health 
Research’s Health Technology Assessment Programme now routinely request the assessment of cost-
effectiveness to be ‘piggybacked’ on Randomised Controlled Trials (RCT’s) [1-3]. While there are 
several types of RCT’s used in medical research, factorial trials are becoming more prevalent in a 
context where health care research budgets are increasingly constrained.  
Factorial trials “test the effects of two or more interventions simultaneously using various 
combinations of the interventions within the same trial” [4]. There are several factorial designs, with 
the most common being the 2x2 which assesses two interventions with each one of them having two 
levels. For example, in a 2x2 factorial trial of self-management options for hand osteoarthritis, 
patients can be randomised to either of the following interventions: usual care, joint protection, hand 
exercises or a combined intervention (joint protection plus hand exercises). This allows for more 
information to be obtained in a single trial at a reduced overall cost [5]. In addition, factorial trials 
allow for the investigation of interactions between the treatments under scrutiny [6-7], and in the 
absence of interactions, they provide greater power than traditional multiple-arm trials of similar 
sample size evaluating the same interventions [8]. 
As a consequence, there is now a growing interest in employing these designs in trial-based economic 
evaluations [9]. However, unlike in the analysis of clinical outcomes, where the methods of analysis 
are well established, methods for the economic analysis of factorial trials remain unclear [10, 11]. 
Recent research suggested that the appropriate analysis of factorial designs in  economic evaluations 
is important, not only because interactions are more likely to occur in economic data but also because 
economic evaluations focus on the estimation of incremental cost-effectiveness ratios (ICERs) as 
opposed to hypothesis testing which is the main focus of clinical studies [10]. There is therefore a 
greater potential for bias which can affect the validity of results if the analysis is not carried out 
appropriately. In addition, this type of trial leads to a reduction in sample size if interactions are 
accounted for. This is problematic because most two arm trials are known to be underpowered for the 
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economic analysis and as a consequence, the factorial trial could potentially lead to further uncertainty 
in economic outcomes [11]. Even though these challenges have been identified, there is still 
uncertainty about how to overcome them.  
 The objective of this study is to systematically review economic evaluations conducted alongside 
factorial trials with the aim of exploring the empirical methods involved  and to offer 
recommendations that could potentially assist in the development of good practice guidelines in this 
context. To the best of our knowledge, no other study has conducted a systematic review of economic 
evaluations alongside factorial trials. 
METHODS 
A systematic review of economic evaluations alongside factorial trials was conducted following the 
guidelines outlined by the UK Centre for Review and Dissemination (CRD) [12]. In the absence of 
Medical Subject Heading (MeSH) for factorial trials and economic evaluations, search terms, 
including truncation where appropriate, included the terms “cost-benefit analysis”, “cost-effectiveness 
analysis”, “cost-utility analysis”, “economic evaluation”, “factorial design” and “factorial trial”.  The 
following electronic databases were searched for relevant studies published for all years: CENTRAL 
(Cochrane Wiley), MEDLINE (Ovid), EMBASE (Ovid), EconLit (EBSCO), NHS EED (Cochrane 
Wiley), Science Citation Index (ISI) and Conference Proceedings Citation Index (ISI).  In addition to 
this, a methodological research in the Cochrane Methodology database (Cochrane Wiley) and BioMed 
Central portfolio of journals was also conducted. The final search strategies across the different 
databases are detailed in Table 1. 
To be included in the review, studies had to be full economic evaluations conducted alongside a 
factorial trial. Studies were excluded if they were partial or non-economic evaluation studies, cohort 
studies, case-control studies, systematic reviews, study protocols or commentaries. Non-English 
studies and grey literature were also excluded. 
Literature search was carried out between July and August 2013 in two stages. First, titles and 
abstracts were screened to identify potentially relevant papers. The second stage involved screening 
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5 
 
the full papers considered to be potentially relevant. The screening process in both stages was done 
against the inclusion and exclusion criteria. The reference lists of the papers identified after the 
second screening process were also screened for additional relevant papers.  A quality assessment was 
not conducted because the focus of the review was to explore the methodologies that have been 
employed in practise for the economic analysis of factorial trials and not the validity of the estimates 
obtained from the included studies. Thus, all the relevant studies identified from the selection process 
were subsequently considered for data extraction. For each of the studies included in the review, data 
were extracted concerning the perspective of the study and type of economic evaluation, cost and 
outcomes considered and method of analysis of factorial trials.  
RESULTS 
The electronic database search identified 135 potentially relevant papers of which 18 were duplicates. 
Out of the 117 remaining papers, 92 were excluded after the screening of titles. A thorough 
assessment of the 25 papers identified to be potentially relevant led to the exclusion of a further 13 
papers from the list, limiting the number of papers to 12. The 13 papers were excluded for the 
following reasons; 7 of them were study protocols, 3 were systematic reviews and 3 were not full 
economic evaluations. The reference lists of the 12 relevant papers were also screened and this led to 
the identification of 4 additional papers. A total of 16 papers were therefore included in the review. 
Figure 1 shows a flow chart of the papers identified, retrieved and retained or excluded at each stage 
of the review process.   
Summary of selected studies 
As shown in table 2, the studies included in the review were published between 2003 and 2013. Of 
these, 15 were ‘2x2’  trials and one was a ‘4x2’ trial. The included studies were conducted across 
eight different countries: Chile [13], the UK [14-21], New Zealand [22, 23], Pakistan [24], Sweden 
[25], Netherlands [26], Malawi [27] and the USA [28]. Most studies were related to musculoskeletal 
disease (seven studies) or cardiovascular disease (five studies). 
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Perspectives and type of economic evaluation undertaken 
Studies were conducted from either a societal [13,23,24], a health service [14,15,17,20,21,26,27,28], 
or patient perspective [19]. Three studies considered both a health service and societal perspective 
[16,22,25] and one considered all three [18]. In all the studies, the reason for adopting a particular 
perspective was given and this was appropriately followed for collecting the right cost data within the 
boundaries of the perspective adopted. 
Two types of economic evaluations were mainly undertaken across the sixteen studies. These are cost-
effectiveness analysis (CEA) and cost-utility analysis (CUA) (Table 2). CEA was undertaken in six 
studies, [13,17,19,23,26,27] whereas CUA was undertaken in nine studies, [14-16,20-22,24,25,28] 
with one study undertaking both cost-consequence and cost-utility analysis [18]. All studies gave a 
justification of why they employed each economic evaluation technique and it was found to be 
appropriate to the research objectives. The sample size of most studies (approximately 63%) was less 
than 800 participants. Only two studies recruited more than 3000 participants. The sample sizes were 
calculated to detect the clinical effects in all studies. Studies differed in terms of what constituted the 
control group for their research. Eleven studies [13,15,17-21,23,25,26,28] used ‘usual care’ as the 
control group whereas five studies [14,16,22,24,27] used a placebo.  
Costs and outcomes 
Six studies had their primary outcome of interest reported in cost per unit effect [13,17,19,23,26,27] 
whereas ten studies reported their primary outcomes in cost per Quality Adjusted Life Year (QALY) 
gained [14-16,18,20-22,25,28] or cost per Disability Adjusted Life Year (DALY) averted [24]. In 
terms of costing, all the studies adopted the ingredient approach (where estimates of total resource use 
are multiplied by their respective unit prices) to estimate the cost of the interventions. In all studies 
where the trials were conducted over a time horizon of one year, cost and QALYs were not 
discounted whereas in studies with larger time horizon costs and QALYs were discounted.  
Analytical approaches to the economic analysis of factorial trials 
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Although not explicitly stated, two methods of analysis were identified across the studies; within-the-
table approach [14-15,18-20,22,24,25,27,28] and at-the-margins approach [13,16,17,23,26]. The 
within-the-table approach implicitly assumes that the interventions within the factorial design are 
mutually exclusive and therefore considers each of them as a separate treatment strategy allowing the 
effect of interactions to be easily seen [29]. The at-the-margins approach implicitly assumes that the 
interventions under investigation are independent and there is no interaction between treatments. The 
trial is therefore analysed as though it were overlapping arms of an RCT comparing the effects of 
treatments separately [29]. One study considered both methods and stated that the reason for 
employing both methods was to provide the most relevant information for policy makers (within-the-
table approach) and to carry out the analysis in line with the convention for a factorial design (at-the-
margins approach) [18]. A summary of the characteristics of both approaches are presented in table 3. 
It should be noted that apart from the choice of approach in the clinical study and the objective of the 
economic analysis, other factors such as sample size, disease area or comparator did not seem to have 
an influence on the choice of approach. 
 A thorough assessment of the studies reviewed indicated that, none of the studies tested interactions 
between treatments in terms of costs and outcomes nor gave a detailed explanation on how they were 
going to account for the factorial nature of the trial. The only instance where reference was made to 
interaction in cost was the study by The UK BEAM trial team [14], where they mentioned a 
comparison of four distinct treatments although cost showed no interaction between treatments. In all 
other instances where studies mentioned an interaction was to reiterate whether any statistically 
significant interaction was evident in clinical outcomes, which then informed the decision about 
which method of analysis to adopt rather than testing for interactions in the economic outcomes.  
DISCUSSION  
The literature search indicated that two methods (within-the-table and at-the-margins approach) are 
commonly used in the economic analysis of factorial trials. The choice of method was found to be 
mainly influenced by the method adopted in the clinical study. It is therefore apparent that for some of 
the studies, even though the clinical trial detected interactions, if the objective was to calculate the 
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separate ICERs for the factors, at-the-margins approach was employed instead of the within-the-table 
approach and vice-versa [14].    
None of the studies explored interactions between economic outcomes or stated the reasons why such 
interactions were not expected to occur. This is problematic as economic outcomes are different from 
the clinical ones, and thus special considerations should be given to their analysis. This may be due to 
a lack of clear guidance on how economic evaluations alongside factorial trials should be conducted 
and their methodological challenges. 
One such challenge may relate to the sample size of the trial. In all studies, sample sizes used were 
calculated with the purpose of detecting the clinical effects of the interventions under scrutiny. The 
problem that arises here is that some trials may be inadequately powered to detect plausible clinical 
interactions [7,30], and thus the absence of proof of evidence for interactions is equated to proof of 
absence of evidence for interactions in the clinical outcomes [30]. Given that interactions are more 
likely to occur in economic outcomes rather than the clinical [10] this assumption is likely to be 
invalid. Even when interactions in economic outcomes are identified, conducting the appropriate 
analysis within-the-table may result in further loss of power and greater uncertainty to the economic 
results.  
It is also worth stating that, unlike clinical outcomes that are generally normally distributed, economic 
outcomes generally follow a skewed distribution and are associated with a higher variance, which 
impact on the way they should be analysed [31,32]. Therefore, even if the trial is adequately powered 
to detect the main difference in clinical outcome, it will be typically underpowered for the analysis of 
economic outcomes. But as can be seen from the sample sizes employed in the various trials, the issue 
of sample size in relation to the detection of interactions (in economic outcomes) and the use of 
appropriate sample size in relation to the distribution of the economic outcomes for their effective 
analysis were not appropriately taken into consideration by almost all the studies. 
Only one study [18] employed both the at-the-margins  and within-the-table approaches, and even 
though this study, like the rest, did not give an explicit explanation of how the factorial nature of the 
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trial was accounted for when the economic variables were analysed, it may be argued that presenting 
both analyses is more informative, even when they result in contradicting recommendations. In terms 
of economic evaluation in general, there were consistencies with respect to the methodological and 
practical aspects. These consistencies can be attributed to the immense literature and guidelines 
available for methodologically robust economic evaluations. Hence researchers have a clear 
understanding and direction on how economic evaluations should be conducted and in most cases, if 
not all, follow it accordingly [33-37]. 
To the best of our knowledge, this is the first study to review economic evaluations conducted 
alongside factorial trials and therefore provides a description of the current state of play in the 
economic analysis of factorial trials. A possible limitation is the broad nature of the research question. 
This study was not limited to a particular disease area and it is quite possible that some studies might 
have been missed out. However, we made every effort to identify all relevant studies by developing 
the search strategy with advice from an information specialist.    
The increasing pressures on health care and research budgets are likely to be associated with an 
increase in the use of factorial trials. This study highlighted the inconsistent use of methods in the 
health economic analysis of factorial trials. Few studies have compared methods for the analysis of 
factorial trials. One study found that the different methods led to different conclusions [9], whilst the 
other found that choice of method did affect the conclusions of the study. However, the degree to 
which the intervention was considered cost-effective varied with the different approach i.e. the 
probability of the intervention being cost-effective differed with the various approaches [11].  
Further research is still required in order to evaluate the impact of alternative methods on policy 
recommendations and establish good practice guidelines on the design and economic analysis of 
factorial trials. Until a consensus is reached with respect to the economic analysis of factorial trials, it 
is suggested that researchers should test for interactions in economic outcomes before deciding on the 
primary analysis and explore alternative approaches in a secondary analysis. This can be achieved by 
using a regression approach, which can easily be adapted to take the form of a within-the-table or at-
the-margins approach by either including or excluding an interaction term in the regression model 
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[29]. When such interactions are unlikely to appear, the reasons should be explicitly stated. Such an 
approach will potentially ensure that the economic and other benefits of factorial trials are not 
translated into suboptimal policy recommendations.   
EXPERT COMMENTARY 
In an increasingly resource constrained environment, there is growing interest in employing factorial 
designs, which assess two or more interventions simultaneously using various combinations of the 
interventions within the same trial. Although methods for the analysis of clinical endpoints alongside 
factorial trials are well established, there is limited methodological guidance for the economic 
analysis. Most published economic evaluations assume no interaction between interventions and are 
inconsistently reported. Overlooking potential interactions on cost and outcome data may introduce 
bias and result in suboptimal policy recommendations. Further work is required to evaluate the impact 
of alternative methods on results from cost-effectiveness analyses alongside factorial trials. 
FIVE YEAR VIEW 
The increasing pressures on health care and research budgets are likely to be associated with an 
increase in the use of factorial trials and a corresponding increase in economic evaluations conducted 
along such trials. With the limited guidance available, it is expected that the inconsistent use of 
methods in the health economic analysis of factorial trials will continue. However, with the 
publication of additional studies highlighting the issues surrounding the economic analysis of factorial 
trials and the potential policy implications, there would be an increased awareness amongst 
resarchers. We expect to see more research comparing alternative analytical approaches and hope that 
this would lead to an increase in the development of methods and guidance for the economic analysis 
of factorial trials over the next five years.   
 
 
KEY ISSUES 
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• There is a growing interest by health economists in employing factorial trials when analysing 
economic data in trial-based economic evaluations. However, methods for the economic 
analysis of factorial trials remain unclear and there seems to be limited guidance on which 
method is the most appropriate and under which circumstances. 
• The results from this study showed that two different methods: ‘within-the-table’ and ‘at-the-
margins’ approaches were used for the analysis. However, with the exception of one study, all 
others did not consider interactions in costs and outcomes or give a detailed explanation of 
why a particular approach was adopted. 
• This review found that although there was consistency in the application of general principles 
for conducting economic evaluations, there was lack of agreement with respect to methods for 
the economic analysis of factorial trials. 
• Further research is required in order to evaluate the impact of alternative methods on policy 
recommendations and establish good practice methods on the design and economic analysis 
of factorial trials. 
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